GRO Biosciences

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.


Our Team

The GRO Biosciences team brings together industry-leading expertise in synthetic biology, protein design, and therapeutic protein development.


George Church

George is a pioneering synthetic biologist with foundational contributions to genome sequencing, DNA synthesis, and protein engineering. George led the development of the genomically recoded organisms (GROs) at the core of the GRO Biosciences platform. George is a co-founder and leads the company's Scientific Advisory Board.


Andrew Ellington

Andrew is a field leader on using evolutionary techniques to engineer biopolymers and cells. Andrew led the development of key protein translational machinery to incorporate non-standard amino acids into proteins using GROs. Andrew is a co-founder and member of the company's Scientific Advisory Board. 


Daniel J. Mandell
Chief Executive Officer

Dan is a leading expert in synthetic biology and protein engineering. Together with George Church, he used GROs to produce the first proteins with stability and function dependent on non-standard amino acids.


Marc Lajoie
Co-founder and Advisor

Marc led the research effort to produce the first GROs with George Church, laying the foundation for the GRO Biosciences platform. Marc advises the company on genome engineering and design, and protein engineering with non-standard amino acids.


Dana Braff
Principal Scientist

Dana is a leading innovator in microbial engineering and molecular diagnostics. With Jim Collins at MIT, Dana co-lead the development of programmable genetic circuits that enable a new generation of tools to confront global health crises.

Scott Radogna
Research Associate

Scott is an experienced molecular biologist who has engineered microbial systems for light-inducible gene expression. Scott provides broad operational support for the company’s product development pipeline.


Christopher Gregg
Chief Scientific Officer

Christopher developed technologies for multiplexed genome engineering in microbial systems under George Church. Christopher brings leading expertise in genome design and microbial fermentation.


Ross Thyer
Co-founder and Advisor

Ross developed protein translational machinery for key non-standard amino acids in GROs to stabilize therapeutic proteins. Ross advises the company on directed evolution, chassis optimization, and biochemical analysis of target therapeutic proteins.


Marisha Collins
Principal Scientist

Marisha is a scientist with an extensive background in microbial gene editing, directed evolution, and genomic library analysis. Her work focuses on optimizing genetic pathways to produce proteins enhanced with non-standard amino acids.


Benjamin Stranges
Principal Scientist

Benjamin is an expert in protein biochemistry who led research into polymerase engineering and nanopore sequencing with George Church. Benjamin also brings expertise in protein design and biophysical assays.


Justin Feng
Principal Scientist

Justin is an expert in metabolic engineering and synthetic biology. Together with George Church, Justin used protein engineering to produce the first modular, generalizable approach to monitor the abundance of small molecule metabolites across all domains of life.


Bijou Bose
Principal Scientist

Bijou is an expert in bacterial genetics, molecular biology, and recombinant protein production. She previously developed bacterial therapeutics for a range of inflammatory diseases and cancer, and has researched microbial gene transfer and natural competence.